-
A new and as yet unpublished study has raised increased concern about the relationship between rofecoxib (Vioxx), Mercks blockbuster COX-2 inhibitor, and cardiovascular events.
-
-
Headaches commonly attributed to sinus are very likely to be migraines.
-
Studies on HCV infection resolution show that PBMC HCV-RNA may remain, despite clearance of the virus from plasma.
-
The FDA has approved a new drug for the management of alcohol dependence.
-
Erythromycin use is associated with a 2-fold increased risk of sudden cardiac death and a 5-fold increase in those who concurrently receive other medications that significantly inhibit its metabolism by CYP3A4.
-
Rifaximin (Xifaxan) has rreceived US FDA approval on May 25, 2004, for the treatment of travelers diarrhea caused by enteropathogenic (non-invasive) Eschericiha coli in individuals at least 12 years of age. Rifaximin is a rifamycin that is poorly absorbed (< 0.4%) from the gastrointestinal tract, and thus achieves very high concentrations in the feces.
-
-
-
Isolated pulmonic valve endocarditis is the topic of an interesting article from the Cleveland Department of Veterans Affairs Medical Center. Hamza and colleagues reported 3 of their own cases, involving men ages 47, 64, and 76, none of whom were intravenous drug addicts (IVDA). In 2 of the patients, Enterococcus faecalis was the causative pathogen, and in the other patient, a coagulase-negative staphylococcus was the pathogen.